Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
Mary Kiige, Founder of Kikwetu Digital Solutions and Digital Innovation Strategist, has shared a post on LinkedIn:
“Can BHOC – Biological Hemoglobin Oxygen Carrier Replace Blood?
The short answer: No!
But here’s why that matters, and why it’s still revolutionary.
What BHOC cannot do:
It doesn’t replace platelets or plasma proteins.
It can’t provide clotting factors or immune cells.
It’s not a complete substitute for blood transfusion.
What BHOC can do:
Deliver oxygen instantly to tissues when red cells can’t.
Work for all blood types (no cross-matching needed).
Stay shelf-stable for 3+ years at room temperature.
Serve as a bridge therapy, buying time until blood or definitive treatment is available.
Real-world use:
Approved in South Africa since 2001.
Used under FDA Expanded Access in the U.S. for patients when blood was not an option.
Applied successfully in trauma, surgery, transplantation, and rare antibody cases.
The takeaway:
BHOC isn’t a blood replacement, it’s a lifesaving oxygen bridge.
When blood is scarce or unavailable, it creates the one thing medicine needs most: TIME!”
Stay updated with Hemostasis Today.
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 06:22Noa Kabera Joins EAHAD as Project Coordinator to Advance Haemophilia and Allied Disorders Care
-
Sep 8, 2025, 03:48Blood Podcast Alert: Voxelotor Drops, Pediatric SCD, Thrombosis in VEXAS Syndrome and TKIs in ALL
-
Sep 7, 2025, 16:14Paddy Barret on Thin Cap Fibroatheroma's Outcomes
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 7, 2025, 14:11New RPTH Journal Research: Statins Reduce Thrombosis Risk but Not Severity of Pulmonary Embolism
-
Sep 7, 2025, 13:37Unfractionated Heparin Dosing in ECMO: A Systematic Review and Meta-Analysis
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress
-
Sep 8, 2025, 05:27Kerry Bozza Funkhouser at BIC 2025 Roundtable on Heavy Menstrual Bleeding and Rare Bleeding Disorders